A handful of big names in drug discovery and development are among the 500 “most responsible,” according to Newsweek.

The outlet published its “America’s Most Responsible Companies 2022” list, marking the third installment of the compilation (in partnership with Statista), this time expanded to include 500 of the largest public corporations around. Companies were judged with an overall score out of 100 that combined assessments on environmental, social and corporate governance performance.

Gilead Sciences (NSDQ:GILD), Merck (NYSE:MRK) and Pfizer (NYSE:PFE) were among the pharmaceutical companies to land a spot in the top-500, with a number of other drug development, pharmaceutical processing and manufacturing companies included.

The highest-ranking company was Gilead in sixth, landing an overall score of 89.9 points (90.6 environmental, 81.1 social and 98.2 corporate governance).

Merck was next-best in ninth at 89.3 points (94.6, 81.4, 92.1), with Biogen placing 11th at 89.1 points (84.4, 86.2, 96.9) and Pfizer registering within the top-50 at 47th with 85.3 points (87, 88.8, 80.3).

Other pharmaceutical companies in the top-500 included Regeneron (103rd), West Pharmaceutical Services (118th), Amgen (146th), Viatris (167th), McKesson (224th), Vertex Pharmaceuticals (234th), United Therapeutics (253rd), Omnicell (314th), Catalent (347th) and Bristol-Myers Squibb (414th).

---

Filed Under: Drug Delivery, Drug Discovery, Drug Discovery and Development
Tagged With: Amgen, Biogen, Bristol-Myers Squibb, Catalent, Gilead Sciences, McKesson, Merck, Omnicell, Pfizer, Regeneron, United Therapeutics, Vertex Pharmaceuticals, Viatris, West Pharmaceutical Services
 

---